![](http://www.ecns.cn/hd/2020/05/29/d6e766b63d794d5f96bff2ebae49961d.jpg)
A pharmacist displays a box of Plaquenil (hydroxychloroquine) at a drugstore in Paris, France, April 29, 2020. France on Wednesday banned the use of malaria drug hydroxychloroquine to treat patients suffering severe forms of COVID-19, the disease caused by the novel coronavirus. (Photo by Aurelien Morissard/Xinhua)
![](http://www.ecns.cn/hd/2020/05/29/222b24a3646b4051934897cd1a65a063.jpg)
A box of Plaquenil (hydroxychloroquine) is seen at a drugstore in Paris, France, April 29, 2020. France on Wednesday banned the use of malaria drug hydroxychloroquine to treat patients suffering severe forms of COVID-19, the disease caused by the novel coronavirus. (Photo by Aurelien Morissard/Xinhua)
![](http://www.ecns.cn/hd/2020/05/29/2ac51bd5f2cc4e038ccd1429c23c926a.jpg)
A box of Plaquenil (hydroxychloroquine) is seen at a drugstore in Paris, France, April 29, 2020. France on Wednesday banned the use of malaria drug hydroxychloroquine to treat patients suffering severe forms of COVID-19, the disease caused by the novel coronavirus. (Photo by Aurelien Morissard/Xinhua)
![](http://www.ecns.cn/hd/2020/05/29/bb94e83b9ae445459e6a2fb65ec28527.jpg)
A pharmacist displays a box of Plaquenil (hydroxychloroquine) at a drugstore in Paris, France, April 29, 2020. France on Wednesday banned the use of malaria drug hydroxychloroquine to treat patients suffering severe forms of COVID-19, the disease caused by the novel coronavirus. (Photo by Aurelien Morissard/Xinhua)